Last reviewed · How we verify
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
This study is a multicenter, prospective, randomized phase 3 clinical study comparing the efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone) in CIA patients with functional iron deficiency.
Details
| Lead sponsor | Hallym University Medical Center |
|---|---|
| Phase | PHASE3 |
| Status | UNKNOWN |
| Enrolment | 312 |
| Start date | Wed Mar 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Anemia
Interventions
- Ferric Derisomaltose Injection
- Darbepoetin Alfa Injection
Countries
South Korea